Cancer
Conditions
Keywords
ctDNA, Next-Generation Sequencing, Oncology
Brief summary
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Interventions
None listed
Sponsors
Tempus AI
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. ≥18 years of age 2. Willing to participate in the research 3. Able to provide informed consent 4. Must be diagnosed with cancer
Exclusion criteria
1\. Not willing or able to have additional blood samples collected
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in ctDNA from baseline, on-treatment and post-treatment blood samples. | 5 years | Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Generation of DNA, RNA, immune and other multiomic datasets. | 5 years | Use blood and tissue based next generation sequencing to uncover biomarkers that may predict outcomes, identify markers related to disease, identify markers related to mechanism of drug action, and inform future research. |
Countries
Puerto Rico, United States
Contacts
CONTACTLauren Lopez
STUDY_DIRECTORMichelle Ting-Lin, MD
Tempus AI, Inc.
Outcome results
None listed